Fresenius Medical Care AG (FMS) Given a $48.00 Price Target at SunTrust Banks Inc.
Fresenius Medical Care AG (NYSE:FMS) has been assigned a $48.00 price target by equities researchers at SunTrust Banks Inc. in a note issued to investors on Thursday. The brokerage presently has a a “buy” rating on the stock. SunTrust Banks Inc.’s target price would suggest a potential upside of 16.34% from the stock’s current price.
Several other equities research analysts also recently weighed in on the stock. Jefferies Group upgraded shares of Fresenius Medical Care AG from an “underperform” rating to a “hold” rating in a research note on Friday, July 8th. Citigroup Inc. upgraded shares of Fresenius Medical Care AG from a “neutral” rating to a “buy” rating in a research note on Tuesday, September 6th. Goldman Sachs Group Inc. reiterated a “buy” rating on shares of Fresenius Medical Care AG in a research note on Wednesday, September 21st. Berenberg Bank reiterated a “buy” rating on shares of Fresenius Medical Care AG in a research note on Tuesday, August 9th. Finally, DZ Bank AG reiterated a “neutral” rating on shares of Fresenius Medical Care AG in a research note on Friday, September 16th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $44.33.
Shares of Fresenius Medical Care AG (NYSE:FMS) traded up 0.85% during midday trading on Thursday, reaching $41.61. The company’s stock had a trading volume of 152,343 shares. Fresenius Medical Care AG has a 12-month low of $38.71 and a 12-month high of $47.52. The stock has a 50-day moving average of $43.87 and a 200 day moving average of $43.82. The firm has a market capitalization of $25.44 billion, a P/E ratio of 23.07 and a beta of 0.58.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/13/fresenius-medical-care-ag-fms-given-a-48-00-price-target-at-suntrust-banks-inc.html
Fresenius Medical Care AG (NYSE:FMS) last announced its earnings results on Tuesday, August 2nd. The company reported $0.96 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.92 by $0.04. The company earned $4.42 billion during the quarter, compared to the consensus estimate of $4.54 billion. Fresenius Medical Care AG had a net margin of 6.40% and a return on equity of 9.66%. Equities research analysts predict that Fresenius Medical Care AG will post $2.01 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Ngam Advisors L.P. increased its position in Fresenius Medical Care AG by 52.4% in the first quarter. Ngam Advisors L.P. now owns 22,301 shares of the company’s stock worth $983,000 after buying an additional 7,666 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Fresenius Medical Care AG by 1.5% in the first quarter. JPMorgan Chase & Co. now owns 134,551 shares of the company’s stock worth $5,930,000 after buying an additional 1,950 shares during the last quarter. M&T Bank Corp purchased a new position in Fresenius Medical Care AG during the first quarter worth $1,459,000. BB&T Securities LLC purchased a new position in Fresenius Medical Care AG during the first quarter worth $692,000. Finally, Goldman Sachs Group Inc. boosted its position in Fresenius Medical Care AG by 12.3% in the first quarter. Goldman Sachs Group Inc. now owns 133,575 shares of the company’s stock worth $5,888,000 after buying an additional 14,609 shares during the last quarter. Institutional investors own 2.33% of the company’s stock.
About Fresenius Medical Care AG
Fresenius Medical Care AG & Co KGaA (FMC AG & CO. KGAA) is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end stage renal disease (ESRD), as well as other healthcare services. The Company operates through four segments: North America, Europe, Middle East, Africa (EMEA), Asia-Pacific and Latin America.
Receive News & Ratings for Fresenius Medical Care AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG and related companies with MarketBeat.com's FREE daily email newsletter.